Document is current
Any future updates will be listed below
-
Authors
Leuzy, Antoine https://orcid.org/0000-0003-4542-7879
Mattsson‐Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
Dage, Jeffrey L https://orcid.org/0000-0002-2192-1699
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
-
Funding
Funding for this research was provided by:
Swedish Research Council (2016‐00906)
Knut and Alice Wallenberg foundation (2017‐0383)
Marianne and Marcus Wallenberg foundation (2015.0125)
Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University
Swedish Alzheimer Foundation (AF‐939932)
Swedish Brain Foundation (FO2021‐0293)
Parkinson foundation of Sweden (1280/20)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Skåne University Hospital Foundation (2020‐O000028)
Regionalt Forskningsstöd (2020‐0314)
Swedish federal government under the ALF agreement (2018‐Projekt0279)
- License Information
-
More Information
Article History
Received: 8 April 2021
Revised: 2 November 2021
Accepted: 5 November 2021
First Online: 3 December 2021
Conflict of interest
: AL, NMC, SJ, and SP report no disclosures. JLD is a former employee of Eli Lilly and Company. OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche.
